AUTL · NASDAQ · Biotechnology

Autolus Therapeutics (ADR) (AUTL)

Commercializes AUCATZYL while developing programmed T-cell therapies for cancer and autoimmune diseases.

$2.10
After hours+0.06 (+2.94%)
At close$2.04(+5.15%)